INmune Bio's CORDStrom shows promise in RDEB treatment
BOCA RATON, FLORIDA - INmune Bio , Inc. (NASDAQ: NASDAQ:INMB), a clinical-stage biotechnology company with a market capitalization of $212.74 million, announced today its plans to submit regulatory ...
Scotiabank raises INmune Bio stock target to $23 on new therapy
Scotiabank (TSX:BNS) increased its price target for INmune Bio Inc. (NASDAQ:INMB) shares to $23.00, up from the previous target of $22.00, while maintaining a Sector Outperform rating. The stock, ...
Pharmabiz5d
INmune Bio to submit BLA with US FDA seeking approval of CORDStrom to treat recessive dystrophic epidermolysis bullosa in paediatric patients
Boca Raton, Florida Wednesday, February 12, 2025, 16:00 Hrs [IST] ...
dermatologyadvisor5d
Oleogel-S10 Improves Wound Burden in Patients With Epidermolysis Bullosa
Oleogel-S10 is an effective and well-tolerated long-term treatment for epidermolysis bullosa, including patients with severe forms of the disease.